EVLO - Evelo Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.23
-0.55 (-6.26%)
At close: 4:00PM EDT

8.23 0.00 (0.00%)
After hours: 4:29PM EDT

Stock chart is not supported by your current browser
Previous Close8.78
Open9.07
Bid5.02 x 1000
Ask9.60 x 1000
Day's Range8.13 - 9.07
52 Week Range6.32 - 15.89
Volume55,157
Avg. Volume27,817
Market Cap263.719M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire21 days ago

    Evelo Biosciences to Present at Upcoming Investor Conferences in June

    CAMBRIDGE, Mass., May 30, 2019 -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing oral biologics that act on cells in the.

  • GlobeNewswirelast month

    Evelo Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with striking therapeutic effects throughout the body, today announced that management will present a corporate overview at the 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22nd at 8:30am ET. A live audio webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with striking therapeutic effects throughout the body.

  • GlobeNewswire2 months ago

    Evelo Biosciences Reports First Quarter 2019 Financial Results and Recent Business Highlights

    -- Novel Formulation of Monoclonal Microbials Discovered, Preclinical Potency Increased by up to 30-Fold:Plan to Introduce New Formulation into Ongoing Clinical Trials in Second.

  • GlobeNewswire2 months ago

    Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Thursday, May 2, 2019

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that it will host a conference call and live webcast at 8:30 A.M. ET on Thursday, May 2, 2019 to report its first quarter financial results and discuss recent business updates. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

  • GlobeNewswire3 months ago

    Evelo Biosciences to Present at 18th Annual Needham Healthcare Conference

    Evelo Biosciences, Inc. (EVLO) (“Evelo”),  a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that management will present a corporate overview at the 18th Annual Needham Healthcare Conference on Wednesday, April 10th at 2:10pm ET. Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines. Evelo’s product candidates are single strains of microbes, selected for defined pharmacological properties.

  • GlobeNewswire4 months ago

    Evelo Biosciences to Present at 39th Annual Cowen & Co. Health Care Conference

    CAMBRIDGE, Mass., March 04, 2019 -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new.

  • GlobeNewswire4 months ago

    Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

    -- First Patient Dosed in University of Chicago Phase 2a Trial of EDP1503 in Metastatic Melanoma ---- Preclinical Studies Have Shown Non-replicating Monoclonal Microbials.

  • GlobeNewswire4 months ago

    Evelo Biosciences to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 14, 2019

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that it will host a conference call and live webcast at 8:30 A.M. ET on Thursday, February 14, 2019 to report its fourth quarter and full year 2018 financial results and discuss recent business updates. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

  • GlobeNewswire5 months ago

    Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial of EDP1503 in Combination with KEYTRUDA® in Patients with Metastatic Melanoma

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, today announced that the University of Chicago has dosed the first patient in an investigator-sponsored Phase 2a clinical trial evaluating EDP1503 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. EDP1503 is an orally delivered monoclonal microbial product candidate being developed for the treatment of cancer. This open-label clinical trial, led by Dr. Jason J. Luke, M.D., FACP, will evaluate the safety, tolerability, and efficacy of EDP1503 in combination with KEYTRUDA® in up to 70 patients with metastatic melanoma who are previously untreated or who have relapsed following treatment with an anti-PD-1 inhibitor.

  • GlobeNewswire5 months ago

    Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications

    Evelo Biosciences, Inc. (EVLO) (“Evelo”) a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, today announced that it has dosed the first patient in its Phase 1/2 clinical trial of EDP1503 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. EDP1503 is an orally delivered monoclonal microbial product candidate being developed for the treatment of cancer.

  • GlobeNewswire6 months ago

    Evelo Biosciences to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

    Evelo Biosciences, Inc. (EVLO) (“Evelo”),  a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells in the small intestine and drive changes in systemic biology, today announced that management will participate in a fireside chat at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 at 2:00 p.m. ET. Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing monoclonal microbials, a new modality of medicines designed to act on the gut-body network. Evelo’s product candidates are orally-delivered, single strains of microbes, selected for defined pharmacological properties.

  • GlobeNewswire7 months ago

    Evelo Enters into Clinical Trial Collaboration Agreement with Merck

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells in the small intestine and drive changes in systemic biology, today announced that it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the US and Canada). The collaboration will evaluate EDP1503 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in multiple cancer indications.

  • GlobeNewswire7 months ago

    Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis

    Evelo Biosciences, Inc. (EVLO) (“Evelo”) a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells in the small intestine and drive changes in systemic biology, today announced first dosing in its Phase 1b clinical trial of EDP1815 for the treatment of psoriasis and atopic dermatitis. EDP1815 is Evelo’s second monoclonal microbial product candidate being developed for the treatment of inflammatory diseases. "Psoriasis and atopic dermatitis patients are underserved by current medicines, particularly in the moderate patient populations, where the potential efficacy, tolerability and convenience benefits of monoclonal microbials could be profound," said Andrea Itano, Ph.D., head of immuno-inflammatory diseases at Evelo.

  • GlobeNewswire7 months ago

    Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire7 months ago

    Evelo Biosciences to Present at Upcoming Investor Conferences in November

    CAMBRIDGE, Mass., Nov. 07, 2018 -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials designed to act on.

  • GlobeNewswire8 months ago

    Evelo Biosciences Reports Third Quarter 2018 Financial Results and Recent Business Highlights

    -- Approval to Initiate Phase 1b Trial of EDP1815 in Psoriasis and Atopic Dermatitis: Dosing of First Patient Expected in 4Q18 ---- Initiation of Investigator-Sponsored Phase 2a.